ATAI Life Sciences closed a $125M Series C funding round (paywall), the biggest round thus far for a medical psychedelics company.
- The money will go to funding clinical trials, adding more companies and therapies and developing “digital therapeutics tools.”
- The company currently works with psilocybin, ibogaine and arketamine, among other compounds.
- ATAI’s backers include Silicon Valley tycoon Peter Thiel who also invested in Compass Pathways, another psychedelics company which went public on the Nasdaq several weeks ago.
- Is mixing cannabis and psychedelic mushrooms a bad idea?